Sunshine Biopharma is conducting a proprietary drug development program comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and a PLpro protease inhibitor. The company is focused on building a diversified generic pharmaceutical portfolio in Canada while advancing oncology and antiviral therapeutics.
Cyborg Score Rationale
The company underwent a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement for continued listing (June 2026), indicating significant stock price weakness. The company generates revenue from generic drugs but faces capital market pressures and execution risks on early-stage pipeline programs.
Top Insights
Pipeline consists of two early-stage proprietary programs: K1.1 mRNA for liver cancer and SBFM-PL4 protease inhibitor for coronavirus—both preclinical/early development stage
Strong generic drug growth: revenues grew 2,100% in Q1 2023 and 3,600% in Q2 2023 following October 2022 acquisition of Nora Pharma, which contributed the majority of sales
Nasdaq listing compliance at risk: (June 2026) 1-for-10 reverse stock split reflects persistent sub-$1 stock price and capital market distress
Canadian market dependency: approximately 70% of commercial revenue derived from generic drugs in Canada with limited US market presence
Named Competitors
Sandoz — Leading global generic pharmaceutical manufacturer
Viatris — Global generic and specialty pharma company
Teva Pharmaceutical — Major generic and specialty pharmaceutical producer